NewsTechCrunch AI
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Wednesday, September 23, 2026
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Daily healthcare AI brief
Get the free healthcare AI briefing
One concise briefing built from reporting, research, policy, blogs, videos, and full podcast transcripts.
Free. Get a sign-in link by email to finish subscribing. An account is created if needed. Unsubscribe anytime. Already subscribed? Sign in to save and personalize.